{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:58:26Z","timestamp":1790261906700,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Motor Neuron Disease (MND) is a neurodegenerative disorder with low incidence (4\u20138 per 100,000), but high disability and mortality. This study analyzes MND burden in China, the U.S., and Globally from 1990 to 2021, covering trends in incidence, prevalence, mortality, Disability-Adjusted Life Years (DALYs), age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR), and predicts changes for 2022\u20132041.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using Global Burden of Disease (GBD) data, Joinpoint regression analysis identified key turning points, and decomposition analysis quantified the contributions of aging, population growth, and epidemiological factors. The Autoregressive Integrated Moving Average (ARIMA) model forecasted future trends.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 1990 to 2021, the incidence, prevalence, mortality, and DALYs of MND in China, the United States, and globally showed significant increases, with the largest increase observed in mortality (China +126%, USA\u202f+118%, global +156%). The annual average percentage changes (AAPC) were as follows: ASIR (\u22121.10, 0.45, \u22120.15%), ASPR (0.26, 0.39, \u22120.04%), ASMR (0.57, 0.51, 0.58%), and ASDR (\u22120.15, 0.14, 0.25%). Joinpoint regression analysis showed that China\u2019s ASIR declined from 1990 to 2015 and began to rise in 2015, with ASPR continuing to increase and ASMR and ASDR fluctuating. In the US, ASIR continued to rise, ASPR decreased before 1995 and then increased, with fluctuations in ASMR and ASDR. Globally, ASIR and ASPR decreased from 1990 to 1995, increased from 1995 to 2005, and then declined from 2005 onwards, with ASMR continuing to increase. Decomposition analysis indicated that aging populations aged 65 and above were the primary driving factor. Gender and age analysis revealed that males under 69 bear a higher MND burden. Predictions for 2022\u20132041 show that in China, male ASIR will decline, while female ASIR will rise, with ASPR, ASMR, and ASDR remaining stable; in the US, male ASIR will rise, ASPR will first increase and then decrease, with ASMR and ASDR remaining stable; globally, ASIR, ASPR, and ASMR will remain stable, while male ASDR will rise and female ASDR will remain stable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The burden of MND continues to increase in China, the United States, and globally, with elderly males particularly affected, while low- and middle-income countries face more severe challenges. This study provides crucial data for developing global public health strategies and medical policies, aiming to effectively reduce the burden of MND through targeted interventions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1539889","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:11:21Z","timestamp":1747368681000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative analysis of trends in the burden of motor neuron disease in China, the United States, and globally from 1990 to 2021: projections for 2022\u20132041"],"prefix":"10.3389","volume":"16","author":[{"given":"Bo","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuluo","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suifa","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.amjmed.2018.07.012","article-title":"Motor neuron disease: pathophysiology, diagnosis, and management","volume":"132","author":"Foster","year":"2019","journal-title":"Am J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1212\/CON.00000000000000535","article-title":"Diagnosis and clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders","volume":"23","author":"Goutman","year":"2017","journal-title":"Continuum"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1212\/CON.0000000000001345","article-title":"Amyotrophic lateral sclerosis and other motor neuron diseases","volume":"29","author":"Izenberg","year":"2023","journal-title":"Continuum"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"04160","DOI":"10.7189\/jogh.13.04160","article-title":"Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide","volume":"13","author":"Huang","year":"2023","journal-title":"J Glob Health"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"864339","DOI":"10.3389\/fneur.2022.864339","article-title":"The global burden of motor neuron disease: an analysis of the 2019 global burden of disease study","volume":"13","author":"Park","year":"2022","journal-title":"Front Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/S0140-6736(24)00972-3","article-title":"Motor neuron disease: improving quality of life for patients","volume":"403","author":"Lancet","year":"2024","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"GBD 2021 nervous system disorders collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamaneurol.2020.4152","article-title":"Burden of neurological disorders across the US from 1990-2017: a global burden of disease study","volume":"78","author":"Feigin","year":"2021","journal-title":"JAMA Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e059548","DOI":"10.1136\/bmjopen-2021-059548","article-title":"Burden of neurological diseases in Asia from 1990 to 2019: a systematic analysis using the global burden of disease study data","volume":"12","author":"Kang","year":"2022","journal-title":"BMJ Open"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/bs.irn.2024.04.003","article-title":"Current neuroprotective therapies and future prospects for motor neuron disease","volume":"176","author":"Evans","year":"2024","journal-title":"Int Rev Neurobiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/bs.irn.2024.04.004","article-title":"Advances in symptom management and in monitoring disease progression in motor neuron disease","volume":"176","author":"Hobson","year":"2024","journal-title":"Int Rev Neurobiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"GBD 2021 diseases and injuries collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"GBD 2021 causes of death collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(24)00476-8","article-title":"GBD 2021 demographics collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"GBD 2021 risk factors collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1002\/sim.9407","article-title":"Twenty years since Joinpoint 1.0: two major enhancements, their justification, and impact","volume":"41","author":"Kim","year":"2022","journal-title":"Stat Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"107161","DOI":"10.1016\/j.asoc.2021.107161","article-title":"Forecasting the dynamics of cumulative COVID-19 cases (confirmed, recovered and deaths) for top-16 countries using statistical machine learning models: auto-regressive integrated moving average (ARIMA) and seasonal auto-regressive integrated moving average (SARIMA)","volume":"103","author":"ArunKumar","year":"2021","journal-title":"Appl Soft Comput"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40520-021-02017-4","article-title":"Aging tsunami coming: the main finding from China's seventh national population census","volume":"34","author":"Tu","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0140-6736(22)01546-X","article-title":"The path to healthy ageing in China: a Peking University-Lancet commission","volume":"400","author":"Chen","year":"2022","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S2468-2667(19)30160-4","article-title":"Healthy China 2030: moving from blueprint to action with a new focus on public health","volume":"4","author":"Chen","year":"2019","journal-title":"Lancet Public Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.vhri.2017.04.001","article-title":"Healthy China 2030: a vision for health care","volume":"12","author":"Tan","year":"2017","journal-title":"Value Health Reg Issues"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1244042","DOI":"10.3389\/fpubh.2023.1244042","article-title":"The association of the affordable care act with nutrient consumption in adults in the United States","volume":"11","author":"Kirk","year":"2023","journal-title":"Front Public Health"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.maturitas.2020.05.018","article-title":"The World Health Organization (WHO) approach to healthy ageing","volume":"139","author":"Rudnicka","year":"2020","journal-title":"Maturitas"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3109\/09593985.2013.856977","article-title":"The second physical therapy summit on Global Health: developing an action plan to promote health in daily practice and reduce the burden of non-communicable diseases","volume":"30","author":"Dean","year":"2014","journal-title":"Physiother Theory Pract"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/15524256.2021.1938344","article-title":"Integrated home-based palliative Care in Motor Neuron Disease: a case report from low- middle income country","volume":"17","author":"Warrier","year":"2021","journal-title":"J Soc Work End Life Palliat Care"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/21678421.2024.2358793","article-title":"Sex, racial, and ethnic disparities in motor neuron disease: clinical trial enrolment","volume":"25","author":"Tsai","year":"2024","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/cells12111536","article-title":"Altered metabolism in motor neuron diseases: mechanism and potential therapeutic target","volume":"12","author":"Barone","year":"2023","journal-title":"Cells"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"afac147","DOI":"10.1093\/ageing\/afac147","article-title":"The UN decade of healthy ageing: strengthening measurement for monitoring health and wellbeing of older people","volume":"51","author":"Amuthavalli Thiyagarajan","year":"2022","journal-title":"Age Ageing"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e158453","DOI":"10.1172\/JCI158453","article-title":"Biological aging processes underlying cognitive decline and neurodegenerative disease","volume":"132","author":"Gonzales","year":"2022","journal-title":"J Clin Invest"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.3390\/ijms19102937","article-title":"Ageing, cellular senescence and neurodegenerative disease","volume":"19","author":"Kritsilis","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e40771","DOI":"10.2196\/40771","article-title":"Factors influencing adoption and use of telemedicine Services in Rural Areas of China: mixed methods study","volume":"8","author":"Du","year":"2022","journal-title":"JMIR Public Health Surveill"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1539889\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:11:23Z","timestamp":1747368683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1539889\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":32,"alternative-id":["10.3389\/fneur.2025.1539889"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1539889","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"article-number":"1539889"}}